Skip to main content

Novel Anticancer Leads and Probes

Guest Editor(s):

Rahman Shah Zaib Saleem: Lahore University of Management Sciences, Pakistan
Nisar Ullah: King Fahd University of Petroleum and Minerals, Saudi Arabia

Submission Status: Open   |   Submission Deadline: 28 April 2023


BMC Chemistry is calling for submissions for a Collection focused on Novel Anticancer Leads and Probes. Despite over a century of research cancer remains one of the leading causes of global mortality with current treatment options limited both in their efficacy and specificity. Better therapeutics may be found through innovative research on the synthesis, structure-activity relationships and molecular mechanisms of action of novel antitumor drugs.

Meet the Guest Editors

Back to top

Rahman Shah Zaib Saleem: Lahore University of Management Sciences, Pakistan

Dr. Rahman Shah Zaib Saleem is a tenured associate professor at the Department of Chemistry and Chemical Engineering, SBA School of Sciences and Engineering, Lahore University of Management Sciences.  His area of research interest lies in developing next generation chemotherapeutics. His specialties include hit and lead generation, lead optimization and structure-based drug design. He has been working on the modulation of microtubules, centrosomes, FLT3, and Aurora Kinases. 


Nisar Ullah: King Fahd University of Petroleum and Minerals, Saudi Arabia
Nisar Ullah is a Professor in the Chemistry Department at King Fahd University of Petroleum and Minerals. His research interests are broadly in the area of synthetic organic and medicinal chemistry. He is the recipient of Diligence, Dedication and Performance award by Pfizer Ann Arbor in 2005 and Excellence in Research Award by KFUPM in 2019.

About the collection

Despite over a century of research cancer remains one of the leading causes of mortality globally with its burden of disease projected to increase over the next two decades. Current cancer therapeutics suffer from a narrow therapeutic index, limited specificity and the risk of multidrug resistance. We remain a long way away from finding that ‘magic bullet’ to treat cancer.

To help move us further towards that treatment, BMC Chemistry has launched this collection on Noval Anticancer Leads and Probes. It aims to showcase research on synthesis, computational studies, structure-activity relationships and molecular mechanism of action of novel antitumor drugs. 

Areas of interest include, but are not limited to:

  •  
    • Antitumor drugs targeting tubulin and microtubules
    • PARP inhibitors
    • Drugs targeting p53
    • Inhibitors of cancer-relevant kinases (e.g. Aurora kinases, FLT3, ChK1 and ChK2)
    • Drugs acting on apoptotic signalling pathways
    • HSP-90 inhibitors
    • Dual-acting anticancer drugs
    • Development of highly selective probes for proteins relevant to cancer
    • Anticancer drugs acting via reactive oxygen species
    • Anticancer drugs acting via the immune system
    • Natural anticancer compounds
    • Prodrug-based anticancer agents
    • Precision medicine

Contributions to this issue could be in the form of both original research and review articles.


Image Credit
© molekuul.be / stock.adobe.com

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of Research Articles. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Novel Anticancer Leads and Probes" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.